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A Novel Action of Histone Deacetylase Inhibitors
in a Protein Aggresome Disease Model
tion, evident from GFP staining concentrating at the
microtubule organizing center (MTOC). When cells ex-
pressing mSOD-GFP were treated with proteasome in-
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2 Massachusetts General Hospital hibitors (10 g/mlALLN), bright perinuclear structures
characteristic of aggresomes formed in more than 65%Harvard Medical School
Boston, Massachusetts 02115 of cells (Figure 1A and Figure S1A in the Supplemental
Data available with this article online).
We believe the reason that mSOD-GFP accumulates
in aggresomes is because mutations in SOD preventSummary
proper folding, in turn promoting accumulation of un-
folded mSOD protein. To test this, we fractionated COS1Protein inclusions are associated with a number of
cells expressing mSOD-GFP and WTSOD-GFP into de-neurodegenerative diseases including amyotrophic
tergent-soluble and -insoluble fractions. The fraction oflateral sclerosis (ALS) [1]. Whether protein aggregates
fusion protein present in the insoluble fraction is mark-are toxic or beneficial to cells is not known. In ALS
edly higher for mSOD-GFP than for WTSOD-GFP. Evenanimal models, mutant SOD1 forms aggresome-like
in the absence of proteasome inhibitors, the insolublestructures in motor neurons and astrocytes [2, 3]. To
mSOD-GFP protein forms high molecular weight com-better understand the role of protein aggregation in
plexes that are reactive to anti-SOD antibody and resis-the progression of disease etiology, we performed a
tant to SDS denaturation. In the presence of the protea-screen for small molecules that disrupt aggresome
some inhibitor ALLN, these complexes are formed muchformation in cultured cells. After screening 20,000
faster (Supplemental Figure S1B). WTSOD-GFP doescompounds, we obtained two groups of compounds
not form similar complexes (Figure 1B).that specifically prevented aggresome formation. One
These observations are very similar to those madegroup consists mainly of cardiac glycosides and will
previously on mSOD expressed in tissue culture cellsbe the subject of another study. The second group
[6]. In that study, the insoluble mSOD protein complexcontains two compounds: one is a known histone de-
was found not to be ubiquitinated. However, when weacetylase (HDAC) inhibitor, Scriptaid [4], and the other
immunoprecipitated the mSOD-GFP from the insolubleis a Flavin analog, DPD. Cells treated with these mole-
fraction using anti-SOD antibody, we were able to detectcules still contained microaggregates, but these mi-
high molecular weight ladders using anti-ubiquitin anti-croaggregates were not transported to microtubule
body, suggesting that the high molecular weight com-organizing centers (MTOCs). The defect in transport
plex formed by mSOD-GFP was ubiquitinated (Figurewas linked to modulation of the dynein/dynactin ma-
1C). This finding is consistent with previous findings inchinery as treatment with Scriptaid or DPD reversed
animal models of ALS, where the protein inclusionsmSOD-induced insolubilization of the dynactin sub-
found in affected motor neurons react strongly to ubiqui-units P50 dynamitin and P150glued. Our findings suggest
tin antibody [7]. These data convinced us that mSOD-a connection between HDAC activity and aggresome
GFP is a reasonable model to study mSOD aggregation.formation and also lay the groundwork for a direct test
We concluded from these data that mSOD-GFP isof the role of aggresome formation in ALS etiology.
less stable than WTSOD-GFP. It tends to precipitate
and readily forms aggresomes in COS1 cells upon inhibi-
Results and Discussion tion of the protein degradation machinery. We devel-
oped a high throughput assay based on this observation
Mutant SOD-GFP, but Not Wild-Type SOD-GFP, to screen for compounds that disrupt aggresome for-
Forms Aggresomes in COS1 Cells mation.
Mutations in the cytoplasmic metalloenzyme Cu/Zn su-
peroxide dismutase 1 (SOD1) cause about 20% of famil-
ial ALS [1, 5]. Mutant SOD1 forms aggresome-like struc- Several Groups of Compounds Inhibit
tures in patients, tissue culture cells, and animal models Aggresome Formation
of ALS [2, 6–8]. To develop an assay for aggresome To find small molecules that inhibit aggresome forma-
assembly for screening small molecules, we generated tion, we developed a screening protocol using COS1
adenoviruses expressing mutant (A4V, G85R, and G93A) cells infected with adenovirus expressing G85RSOD-
and wild-type (WT)SOD-GFP fusion proteins and ex- GFP (see Supplemental Data).
pressed them in COS1 cells. WTSOD-GFP-expressing After screening 20,000 compounds, we identified 25
cells showed diffuse, uniform cytoplasmic fluorescence compounds that reproducibly inhibited aggresome for-
that was little affected by adding proteasome inhibitors. mation. Subsequent testing allowed us to group the
Cells expressing mSOD-GFP, in contrast, showed gran- screening positives into three categories: microtubule
ular fluorescence, and some showed aggresome forma- inhibitors (9), protein synthesis inhibitors (4), and candi-
date-specific aggresome inhibitors (12) (Figure 2). Mi-
crotubule inhibitors were detected by examining micro-*Correspondence: ching_liu@hms.harvard.edu
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Figure 2. Structures of Hit Compounds and Their Corresponding
PhenotypeFigure 1. Mutant SOD (G85R)-GFP but not WTSOD-GFP Fusion
(A) GFP staining pattern of DMSO control.Protein Forms Aggresomes upon Treatment with Proteasome Inhibi-
(B) -tubulin morphology shown by immunofluorescence stainingtor ALLN
with anti--tubulin antibody (Sigma T5168) under DMSO treatment.(A) Mutant SOD-GFP but not WTSOD-GFP fusion protein forms ag-
(C) GFP staining pattern of cells treated with 2A12, a microtubulegresomes. Fluorescence image of COS1 cells expressing G85R-
destablizer.GFP or WTSOD-GFP fusion protein incubated overnight with or
(D) -tubulin morphology with 2A12 treatment, labeled as in (B).without proteasome inhibitor (10 g/ml ALLN). Scale bar equals
(E) Phenotype of protein synthesis inhibitor 59E19.40 m.
(F) Phenotype of Cardiac Glycoside 54K09.(B) Mutant but not WTSOD-GFP fusion protein forms high molecular
(G) Phenotype of Scriptaid.weight complexes (HMWC) that are resistant to SDS denaturation.
(H) Phenotype of DPD.COS1 cells infected with Adenoviruses expressing mutant (G85R or
(A), (C), and (E)–(H) show GFP staining pattern. Scale bar equalsA4V)-SOD or wild-type SOD-GFP fusion protein were incubated for
40 m.2 days without proteasome inhibitors. Total cell extracts were frac-
tionated into detergent-soluble and -insoluble fractions according
to the experimental procedure. Equal amounts (10%) of extract frac-
tions were immunoblotted with anti-SOD antibody (Calbiochem mainly cardiac glycosides (an example is shown in Fig-
#574597). S, soluble fraction; P, insoluble fraction. ure 2F) and will be discussed elsewhere. The second
(C) The high molecular weight complexes formed by mutant SOD- contains two compounds. The first, 14N02, is a hydrox-
GFP are ubiquitinated. Total cell extracts from cells expressing ei-
amic acid-based histone deacetylase (HDAC) inhibitor,ther mutant (A4V or G85R)-GFP or wild-type SOD-GFP fusion pro-
named Scriptaid [4]. The second, DPD (5-(3-Dimethyl-teins were immunoprecipitated using RIPA buffer with anti-SOD
amino-propylamino)-3,10-dimethyl-10H-pyrimidol[4,antibody according to the standard protocol [17]. The antibody
bound fraction was immunoblotted with anti-ubiquitin antibody 5-b]quinoline-2,4-dione) is a Flavin analog whose effects
(Sigma U5379). Ig LC, IgG light chain. on cells are unknown. The two compounds have differ-
ent structures but give a similar phenotype. The mutant
SOD-GFP fusion protein is present in treated cells at
similar or higher levels than control cells. mSOD-GFPtubule structure in the presence of the small molecule.
An example of this group, compound 2A12, is shown in forms small granular structures throughout the cyto-
plasm of treated cells, but assembly into aggresomesFigures 2C and 2D. Protein synthesis inhibitors were
identified by quantifying total GFP signal and 35S methio- is almost completely inhibited in most cells (Figures 2G
and 2H). The percentage of cells containing aggresomesnine incorporation into total cellular proteins (data not
shown). Compound 59E19 is an example of this group decreases from 77% with DMSO to 15% with 5 M of
Scriptaid and 18% with 5 M of DPD (Supplemental(Figure 2E). Only the specific inhibitors, those whose
activity could not be explained by effects on microtu- Figure S2B). We tested the potent HDAC inhibitors Tri-
chostatin A and Trapoxin [9]. These have a similar effectbules or protein synthesis, were pursued further. These
fell into two groups. The first group is composed of at concentrations of 1 M and 10 nM, respectively, but
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In cells treated with Scriptaid or DPD, the level of
mSOD-GFP is enhanced compared with that in un-
treated cells (Figures 2G and 2H), presumably due to
enhanced transcription from the CMV promoter. We
considered the possibility that the effect of these com-
pounds is due to enhanced expression of SOD-GFP
overwhelming the aggresome assembly pathway. To
test this, we compared the percentage of cells con-
taining aggresomes at different protein expression lev-
els. Total GFP signal per cell was measured and the
cells were assigned to a high or low expression groupFigure 3. Scriptaid and DPD Do Not Block Microaggregation, and
Their Effects Are Independent of Expression Level using an arbitrary cutoff. The fraction of cells assigned
to the high expression groups was higher in the pres-(A) Neither Scriptaid nor DPD solubilized mutant SOD-GFP fusion
protein. COS1 cells expressing G85R-GFP fusion protein were ence of Scriptaid (62%) and DPD (53%) than DMSO
treated with Scriptaid, DPD, or control DMSO overnight. Cells were (37%), as expected. However, expression level did not
then fractionated into detergent-soluble (S) and -insoluble (P) frac- correlate with aggresome assembly. The percentage of
tions according to experimental procedure. The amount of G85R-
cells containing discrete aggresomes is determined byGFP protein in each fraction was examined by immunoblotting with
counting 300 cells randomly for each group. Figure 3Banti-SOD antibody. S, soluble fraction; P, insoluble fraction.
shows that about 73% of control cells contain aggre-(B) The percentage of cells containing aggresomes is similar at
different protein expression levels. Protein expression level was somes regardless of the protein expression level. The
measured by GFP intensity (arbitrary units) in three independent percentage was reduced to no more than 25% and 37%
experiments. Error bars represent standard deviations (SDs). The for treatment with Scriptaid and DPD, respectively (Fig-
differences between treated and untreated are significant according
ure 3B). Since aggresome assembly was similar in highto Student’s t test. p  0.005.
and low expressors, we concluded that the effect could
not simply be due to the enhanced expression of SOD-
GFP protein.are more toxic to cells (data not shown). We therefore
The effect of Scriptaid and DPD is similar to microtu-concluded that HDAC inhibitors inhibit aggresome for-
bule destabilizers such as 2A12 and nocodazole in thatmation in our assay.
mutant protein forms microaggregates that are not
transported to MTOCs. Although the microtubule distri-
Scriptaid and DPD Do Not Block bution is not apparently affected and expression levels
Microaggregation, but Affect the Interaction of dynein/dynactin appear normal, it is possible that
of Misfolded Mutant SOD-GFP Protein inhibition of aggresome assembly by Scriptaid and DPD
with Dynein/Dynactin Machinery might be due to some other effect on dynein/dynactin
To understand how Scriptaid and DPD inhibit aggre- transport. To test this, we measured the fraction of trans-
some formation, we examined their effect on the distri- port proteins that were recruited to insoluble compo-
bution of the aggresome markers, including vimentin nents by cell fractionation (Figure 4). Cells were lysed
and gigantin [10, 11] (see Supplemental Figure S2). In with detergent, separated into soluble and insoluble
cells treated with Scriptaid or DPD, vimentin does not components (see Supplemental Experimental Proce-
form the characteristic ring-like structure found in aggre- dures), and probed with antibodies to dynein/dynactin
some-containing cells (Supplemental Figure S2A, a–f) components. In cells expressing mSOD-GFP, there was
[10, 11]. The close to normal localization of vimentin an increase in the amount of detergent-insoluble
confirms that Scriptaid and DPD block aggresome for- P150glued and P50 dynamitin compared with cells ex-
mation. Additionally, gigantin was mostly concentrated pressing WTSOD-GFP, consistent with the idea that
at the MTOC with a slightly more dispersed distribution these proteins are recruited to insoluble mSOD-GFP
in treated than untreated cells (Supplemental Figure aggregates. There was also a change of solubility for
S2A, g–l). In a nocodazole washout experiment, the as- protein chaperone Hsp70 but not Hsp90 (Figure 4A). This
sembly of the Golgi apparatus was not affected (data latter observation is similar to previous studies showing
not shown) in the presence of these molecules. These that a portion of Hsp70 becomes detergent insoluble in
data suggest that Scriptaid and DPD do not greatly NIH 3T3 cells expressing a mutant form of SOD [12].
affect MTOC formation or Golgi localization and as- When cells expressing mSOD-GFP were treated with
sembly. Scriptaid or DPD, the amount of insoluble P150 de-
One possible explanation is that our compounds pre- creased from 30% to 11% and 16%, respectively (Fig-
vent aggresome function by binding to and solubilizing ures 4B and 4C), and the amount of insoluble P50 dy-
misfolded proteins. To test this, we fractionated cells namitin subunit decreased significantly from 20% to less
expressing mSOD-GFP into detergent-soluble and than 5% (Figures 4B and 4C). The solubility of -tubulin,
-insoluble fractions. In untreated cells, about 55% of a control protein, was not affected by any treatment.
fusion protein is detergent insoluble. Treatment with The amount of insoluble Hsp70 did not change with
Scriptaid and DPD does not change this fraction (Figure compound treatment (data not shown). These data sug-
3A). This indicates that mSOD-GFP still forms protein gest that our compounds may interfere with the interac-
aggregates in the presence of these molecules, consis- tion of the mSOD-GFP aggregates with the dynein/
tent with the appearance of dispersed microaggregates dynactin machinery, explaining the lack of transport to
the MTOC.by the GFP image.
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chinery and how they are recognized by the dynactin
complex.
Deacetylase enzymes can be either cytoplasmic (e.g.,
tubulin deacetylase) or nuclear (e.g., histone deacety-
lase). We found that both Scriptaid and Trichostatin A
inhibited deacetylation of both histones (H3, H4) and
tubulin, indicating that they are a relatively broad inhibi-
tors of deacetylases, but DPD did not, indicating that it
is probably not an HDAC inhibitor (data not shown). A
tubulin-specific deacetylase inhibitor Tubacin [15] had
no effect at concentrations that are selective for tubulin
acetylation (data not shown). These data suggest that
the effect of Scriptaid might require inhibition of histone
deacetylation, consistent with this notion; the effect of
Scriptaid and DPD required transcription (Supplemental
Figure S3).
We hypothesize that Scriptaid and DPD act through
a transcription program that changes the expression
profile of some protein factor(s) that are involved in theFigure 4. Both Scriptaid and DPD Promote the Solubilization of
recognition and binding of protein aggregates by theP150glued and P50 Dynamitin
dynactin complex. Since recognition of aggregates is(A) Like heat shock protein Hsp70, P150glued and P50 dynamitin show
poorly understood, it is difficult at this point to suggestincreases in the fraction of protein that is soluble in cells expressing
mSOD-GFP. COS1 cells expressing either wild-type or G85R-GFP candidate(s) for this induced protein(s). mRNA expres-
fusion protein were fractionated into detergent-soluble and -insolu- sion analysis might reveal candidates, and for such an
ble fractions as described in Supplemental Experimental Proce- approach, our identification of two molecules that mod-
dures. The amount of each protein was measured by immunoblotting
ulate a transcription program by possibly differentusing anti-Hsp70 (Sigma H5147), anti-Hsp90 (Sigma H1775), anti-
mechanisms may be useful.P50 dynamitin (Pharmingen 611002), or anti-P150glued (Pharmingen
It is known from previous studies that formation of610473).
(B) Treatment with Scriptaid and DPD decreased the amount of aggresomes in cells does not affect trafficking between
insoluble P150glued and P50 dynamitin. COS1 cells expressing mutant ER and the Golgi apparatus in tissue culture cells [11].
G85R-GFP were treated with Scriptaid, DPD, and control DMSO. We show here that aggresome formation does cause
Total proteins were fractionated into detergent-soluble (S) and
some dynactin complex to become insoluble and thus,-insoluble (P) fractions according to the experimental procedure.
presumably, sequestered from the normal transportThe amount of P50 dynamitin, P150glued, and tubulin were determined
function. This could be damaging to neurons over-by immunoblotting.
(C) The percentage of insoluble P150glued and P50 dynamitin de- expressing high levels of misfolded proteins. Both
creased in the presence of Scriptaid and DPD. The amount of pro- Scriptaid and DPD promoted the solubilization of dynac-
teins in the soluble and insoluble fractions was calculated using NIH tin subunits in cells expressing mSOD. If sequestration
imaging software and the results were an average of four indepen-
of dynactin by aggregation causes toxicity, treatmentdent experiments. Error bar, SDs. The difference between each pair
of cells with these molecules might be beneficial to neu-of data is significant according to Student’s t test, for P50 dynamitin,
rons containing aggresomes. Experiments are currentlyp  0.02, for P150glued, p  0.03.
underway to test these compounds in ALS transgenic
mice.
In response to various physiological stresses, includ- While this manuscript was under review, a study used
ing heat shock or exposure to toxic agents, cells upreg- genetics to show that the catalytic activity of histone
ulate a conserved set of heat shock proteins via tran- deacetylase HDAC6 was required for aggresome forma-
scriptional regulation of the corresponding genes [13]. tion [16]. In this study, the authors provided evidence
Misfolded proteins are competent to mediate a subset that HDAC6 binds directly to both misfolded protein and
of the responses to heat shock in Saccharomyces cere- the dynein/dynactin transport machinery. Our results
visiae [14]. Previous studies showed that in NIH 3T3 are consistent with their conclusion, and in addition, this
cells stably expressing a mutant form of SOD, the level of study provides small molecule tools for further dis-
Hsp70 is upregulated [12]. We did not see any significant secting the aggresome pathway.
change in the level of Hsp70 and Hsp90 proteins. How-
ever, we did notice that expression of mSOD-GFP Supplemental Data
causes a portion of Hsp70 to become insoluble. Part of Supplemental data including experimental procedures can be
found online at http://www.current-biology.com/cgi/content/full/14/the discrepancy between our data and those of Shinder
6/488/DC1.et al. [12] could be due to the fact that they used stably
transfected cells and we used transient transfection with
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